Analysts Set West Pharmaceutical Services, Inc. (NYSE:WST) Target Price at $355.55

Shares of West Pharmaceutical Services, Inc. (NYSE:WST) have earned an average rating of “Buy” from the fifteen research firms that are presently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have issued a strong buy rating on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $363.1667.

A number of equities research analysts have recently weighed in on the stock. Wolfe Research initiated coverage on shares of West Pharmaceutical Services in a research note on Monday, June 1st. They set an “outperform” rating and a $375.00 target price on the stock. Evercore reissued an “outperform” rating and issued a $410.00 price target on shares of West Pharmaceutical Services in a research note on Monday, July 6th. Barclays upgraded shares of West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $310.00 to $400.00 in a report on Tuesday, June 9th. Stephens reaffirmed an “overweight” rating and set a $360.00 price objective on shares of West Pharmaceutical Services in a research report on Tuesday, June 2nd. Finally, BNP Paribas Exane began coverage on West Pharmaceutical Services in a report on Monday. They set an “outperform” rating and a $447.00 target price on the stock.

Insider Activity at West Pharmaceutical Services

In related news, VP Annette F. Favorite sold 2,817 shares of the company’s stock in a transaction on Monday, April 27th. The stock was sold at an average price of $305.20, for a total value of $859,748.40. Following the sale, the vice president directly owned 16,828 shares of the company’s stock, valued at $5,135,905.60. This represents a 14.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CAO Chad Winters sold 896 shares of the company’s stock in a transaction on Monday, April 27th. The stock was sold at an average price of $300.67, for a total value of $269,400.32. Following the completion of the sale, the chief accounting officer directly owned 1,523 shares in the company, valued at approximately $457,920.41. The trade was a 37.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 0.60% of the company’s stock.

Institutional Trading of West Pharmaceutical Services

A number of hedge funds have recently made changes to their positions in the stock. Elyxium Wealth LLC purchased a new stake in shares of West Pharmaceutical Services in the 4th quarter worth approximately $25,000. CYBER HORNET ETFs LLC purchased a new position in West Pharmaceutical Services during the second quarter valued at $25,000. Cornerstone Planning Group LLC raised its stake in West Pharmaceutical Services by 90.9% during the first quarter. Cornerstone Planning Group LLC now owns 105 shares of the medical instruments supplier’s stock valued at $26,000 after buying an additional 50 shares during the last quarter. Bayban bought a new stake in West Pharmaceutical Services in the fourth quarter worth $27,000. Finally, Private Trust Co. NA boosted its holdings in West Pharmaceutical Services by 156.4% in the fourth quarter. Private Trust Co. NA now owns 100 shares of the medical instruments supplier’s stock worth $28,000 after acquiring an additional 61 shares in the last quarter. 93.90% of the stock is owned by institutional investors.

West Pharmaceutical Services Stock Performance

NYSE:WST opened at $358.18 on Friday. The stock has a market cap of $25.31 billion, a P/E ratio of 47.88, a price-to-earnings-growth ratio of 3.01 and a beta of 1.16. The firm’s fifty day simple moving average is $330.36 and its 200 day simple moving average is $283.09. West Pharmaceutical Services has a twelve month low of $206.80 and a twelve month high of $367.66. The company has a quick ratio of 2.04, a current ratio of 2.71 and a debt-to-equity ratio of 0.07.

West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings data on Thursday, April 23rd. The medical instruments supplier reported $2.13 EPS for the quarter, topping the consensus estimate of $1.68 by $0.45. West Pharmaceutical Services had a net margin of 16.85% and a return on equity of 19.03%. The business had revenue of $844.90 million during the quarter, compared to analyst estimates of $779.67 million. During the same period in the prior year, the business earned $1.45 EPS. The company’s revenue for the quarter was up 21.0% on a year-over-year basis. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. As a group, research analysts predict that West Pharmaceutical Services will post 8.6 EPS for the current year.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.